TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06673966

Intervention type: OTHER
Intervention: Regular follow-up assessments without intervention.
Description: Participants will receive a 3-month follow-up with clinical information, biological samples, and imaging data collected at baseline, 1st and 3rd months. The baseline assessment will include demographic information, medical history and previous medication use. At baseline and follow-up, patients' physical examination data (height, weight, waist and hip circumference, etc.), clinical symptom assessment scales (PANSS, SANS, SAPS, CDSS, CPSS, CGI, GAF, PSP, and SAS) and MCCB cognitive assessment data, blood and cerebrospinal fluid samples, MRI, and EEG data will be collected. Collection and store of blood and cerebrospinal fluid samples for routine laboratory tests and multi-omics including immunohistology, inflammation-related molecules, single-cell sequencing, extracellular vesicles, and other assays.

Intervention type: OTHER
Intervention: Cross-sectional assessment
Description: Volunteers' physical examination data (height, weight, waist circumference, hip circumference, etc.), scale assessments (SCID, SCL-90, and CPSS) and MCCB cognitive assessment data, blood samples, MRI, and EEG data will be collected. Blood was collected and stored for exploring differences between patients and healthy individuals.
Study: NCT05203640

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High repetition (HI)
Description: Participants will perform 15 to 20 repetitions of 7 different exercises at 50% of their one repetition maximum

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate repetition (MOD)
Description: Participants will perform 8 to 10 repetitions of 7 different exercise at 75-80% of their one repetition maximum
Study: NCT04489134

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A
Description: Administration of a 3 mg dose of prolonged-release tacrolimus (Advagraf®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Administration of a 2 mg dose of LCP-tacro (Envarsus®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Administration of a 2 mg dose of LCP-tacro (Envarsus®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B
Description: Administration of a 2 mg dose of LCP-tacro (Envarsus®)
Study: NCT05861375

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibroscan
Description: Fibroscan is a non-invasive device that allows liver exploration painlessly, quickly (a few minutes) and with immediate results. A probe placed on the skin generates an elastic wave completely painlessly and the device measures its speed of propagation in the liver. Liver stiffness is calculated from this speed.
Study: NCT05306847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab will be given intravenously at a dose of 200mg every 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anlotinib
Description: Anlotinib will be given at a dose of 12mg once daily on days 1-14 of a 21-day cycle.
Study: NCT04881344

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser hemorrhoidoplasty
Description: * Under local anesthetic (or general anesthetic if contraindications to local anesthetic),~* A laser optic fiber connected to a diode platform (Leonardo, Biolitec AG, Jena, Germany) will be applied threw a anoscope. After making a 1-mm opening at the external border of hemorrhoid pocket, the fiber will be introduced in the hemorrhoidal tissue. Several pulses, each lasting for 1.2 s, with a 0.6-s pause between pulses, will be delivered to the tissue.~* As a day-case procedure (or short-stay if medical or social factors precluded ambulatory intervention),~* Postoperative care will consist of: normal diet, bulking laxatives, self-irrigation to the anal wound at six times per day and painkiller. Absence for work certificate will be made for 7 days for each patient and they will be told to return to work and normal daily activities as soon as they felt able.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mucopexy
Description: * Threw an anoscope, the hemorrhoidal cushion will be sutured using a half-circle (size 26) needle with a 2-0 poliglecaprone (Monocryl®, Ethicon, USA). Then, a continuous suture will be performed on the mucosa of the anal canal, and will terminate above the dentate line. The hemorrhoidal artery will be ligated by this suture. Then, the ligation will be tied to realize the hemorrhoidopexy.~* Same anesthetic technique and postoperative care as the intervention group. As a day-case procedure (or short-stay if medical or social factors precluded ambulatory intervention).
Study: NCT05030649

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart glasses
Description: The real-time ultrasound image is displayed through head-mounted display Moverio BT-300 (Epson Inc., USA) during the radial arterial cannulation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The real-time ultrasound image is displayed by the ultrasound machine's monitor during the radial arterial cannulation.
Study: NCT05252715

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal ACYW135 Polysaccharide Conjugate Vaccine
Description: Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 meningococcal polysaccharide combined with tetanus toxoid.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal A and C Polysaccharide Conjugate Vaccine
Description: Single intramuscular dose contains 10 µg each of Serogroup A and C meningococcal polysaccharide combined with tetanus toxoid.
Study: NCT04486261

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity strength training
Description: The high-intensity strength training protocol will consist of 2 training sessions per week. The first two weeks will be familiarisation training, where each exercise will be performed in three sets of 10 repetitions at an intensity of 15 repetitions maximum (RM). At week three each session will consist of 3 sets of each exercise corresponding to 10 RM, which will be kept for the remaining part of training intervention. The weights for each exercise will be adjusted throughout the intervention period, so the training load will correspond to 10 RM for each exercise in the entire intervention period.
Study: NCT05868135

Intervention type: BEHAVIORAL
Intervention: eMeistring
Description: Initial face-to-face visit, eight/nine sessions/modules of therapist guided ICBT, final face-to-face visit

Intervention type: BEHAVIORAL
Intervention: eMeistring
Description: Initial face-to-face visit, eight/nine sessions/modules of therapist guided ICBT, final face-to-face visit

Intervention type: BEHAVIORAL
Intervention: eMeistring
Description: Initial face-to-face visit, eight/nine sessions/modules of therapist guided ICBT, final face-to-face visit
Study: NCT04627688

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time restricted feeding
Description: Participants will be advised to eat only during a selected window of 8 hours, and no later than 4pm, with no advice on nutrition quality, quantity or caloric intake. The intervention will include no medication, no medical device, and will last for 2 weeks prior to surgery.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard dietary advices
Description: Participants will be given standard dietary advices, as recommended by the international nutrition guidelines, and thus are not different from common clinical practice.
Study: NCT03503279

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: McGrath MAC® Video Laryngoscope
Description: McGrath MAC® Video Laryngoscope have been developed to secure the airway and improve the management of difficult intubation. McGrath MAC® is a self-contained VL with a single-use blade; its structure is similar to the ML, but without the channel that guides the tube and a mounted LCD screen on the handle that is connected to a miniature camera with a light source at the tip of the blade, allowing the clinicians to directly observe surrounding anatomical airway structures during a tracheal intubation
Study: NCT04650074

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LIDOCAINE 20 mg
Description: 4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine (qsp 6 ml NaCl 0.9%).~Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one:~* 1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle,~* 2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIDOCAINE 20 mg + KETAMINE 20 mg
Description: 4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine + 20 mg Ketamine (qsp 6 ml NaCl 0.9%).~Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one:~* 1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle,~* 2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIDOCAINE 20 mg + KETAMINE 40 mg
Description: 4 injections (on day 1, day 7, day 14, day 28) by mesotherapy of 20 mg Lidocaine + 40 mg Ketamine (qsp 6 ml NaCl 0.9%).~Each mesotherapy session includes 2 steps performed chronologically. It will be done within 2 or 3 minutes each one:~* 1st sequence: intra-epidermal injections of 3 ml by manual technique in crossed lines with a 13 mm x 0.30 needle,~* 2nd sequence : superficial intradermal injections of 3 ml (between 1 and 2 mm) using a technique assisted by a Pistor Eliance injector at a frequency of 200 punctures per minute
Study: NCT06508086

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser ablation technique in the treatment of pilonidal sinus
Description: group (A) will include patients with pilonidal sinus disease who will be operated by sinus tract ablation procedure using 1470 nm Diode laser

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Karydakis technique in the treatment of pilonidal sinus
Description: group (B) will include patients with pilonidal sinus disease who will be operated by Karydakis technique
Study: NCT06508255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early Time-Restricted Eating
Description: Eat between 8:00 and 16:00 for 2 weeks

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late Time-Restricted Eating
Description: Eat between 13:00 and 21:00 for 2 weeks
Study: NCT05720598

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sentinel Node Assessment
Description: The SN assessment will be conducted similarly to the method proposed by Märkl et al. All LNs will be stored in a -80 °C freezer, immediately after retrieval. Within 1 to 3 days, each LN will be individually measured and weighed. Small LNs (\<5 mm in short diameter) will be bisected, and half of the node will be processed for histological evaluation while the remaining half will be used for OSNA analysis. For intermediate-sized LNs (5-10 mm), a middle slice of about 2 mm thickness will be cut out for the histology, and the remaining parts of the node will be processed by OSNA. In large LNs (\>10 mm), at least two slices will be cut out for histology, and the remaining parts of the node will be analyzed by OSNA.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Staging laparoscopy
Description: Pneumoperitoneum (10-12mmHg) will be obtained with Veress needle or 10mm trocar after minilaparotomy. Peritoneal cavity will be thoroughly assessed after insertion of two additional trocars. In cases of macroscopic dissemination, peritoneal cancer index (PCI) will be determined. After switching the optical camera into near-infrared / indocyanine green fluorescence mode, the primary tumor will be visualized, followed by assessment and possible dissection of sentinel lymph node with a high-energy device. The lymph node will be retrieved with a sterile bag, and the area of dissection will be marked with a clip. Trocars will be removed under visual assistance, and the pneumoperitoneum will be released through trocars in order to prevent port-site metastases.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastroscopy with indocyanine green (ICG) injection
Description: Patients will undergo gastroscopy one day prior to staging laparoscopy. The ICG powder contains 0.125 mg/ml. Two milliliters of ICG (0.125mg/ml) solution is injected in the submucosa with into four peritumoral sites, 0.5 ml for each site.
Study: NCT04918862

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron
Description: 210 patients were enrolled, divided into two groups \[Granisetron 1 mg: 105 patients received 1mg granisetron, Granisetron 3 mg: 105 patients received 3mg granisetron\]. The two groups were compared in demographic characteristics (age, gender, weight, and height), hemodynamic parameters (MAP and HR), and duration of surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granisetron
Description: 210 patients were enrolled, divided into two groups \[Granisetron 1 mg: 105 patients received 1mg granisetron, Granisetron 3 mg: 105 patients received 3mg granisetron\]. The two groups were compared in demographic characteristics (age, gender, weight, and height), hemodynamic parameters (MAP and HR), and duration of surgery
Study: NCT04398680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin
Description: Belantamab mafodotin will be administered
Study: NCT06442605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: single-channel uterine fibroid morcellation system
Description: Conventional laparoscopic myomectomy is performed with the use of a single-channel uterine fibroid morcellation system for fragmentation and retrieval of the fibroids during the procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Multi-channel specimen retrieval bag + conventional laparoscopic uterine fibroid morcellator
Description: In conventional laparoscopic myomectomy, a multi-channel specimen retrieval bag is used during the procedure, along with a conventional laparoscopic uterine fibroid morcellator for fragmentation and retrieval of the fibroids.
Study: NCT05763927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib 5mg 2w on/1w off, 21d/cycle, totally 4 cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab 200mg d1, 21d/cycle, totally 4 cycle.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy
Description: 25 Gy in 5 fraction, d22-26.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TME
Description: Surgical resection of the primary tumour in the rectum, 2-4weeks after the last dose of fruquintinib
Study: NCT05458986

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Media Intervention
Description: Watch an educational video

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive usual care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05325996

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Standard Automatic Perimetry Humphrey Field Analyzer
Description: Standard Automatic Perimetry (SAP) using the Swedish Interactive Threshold Algorithm (SITA) Standard Strategy measures the visual field in an ophthalmic setting.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: visuALL H
Description: visuALL H a new portable perimeter measuring the visual field and acuity in a non ophthalmic setting.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: iCare Home Tonometer
Description: iCare HOME tonometer is a device developed for patients/subjects to measure their eye pressure at home.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Spectralis Optical coherence tomography (OCT)
Description: Optical coherence tomography (OCT) is a computerized picture measuring the thickness of the inner layer of the retina that makes the optic nerve.
Study: NCT05107219

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of luminal fluid

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of luminal fluid

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of luminal fluid

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy
Description: Undergo EGD

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy
Description: Undergo EGD

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Esophagogastroduodenoscopy
Description: Undergo EGD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaclotide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plecanatide
Description: Given PO
Study: NCT05525260

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Limonene capsule
Description: Citrus foods rich in D-limonene were forbiden 2 days before taking the drug (washout period), which was maintained after taking the drug.Limonene capsules group and placebo group were used for treatment. The random number is generated by the central randomization system. All the recruiters were divided into placebo control group and limonene capsule administration group. The numbers will be assigned according to random numbers. In this study, qualified subjects were randomly assigned to the treatment group and the placebo control group at a ratio of 1:1. The drug was administered for 12 weeks, 3 times a day, 5 capsules each time.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Limonene capsules(Placebo)
Description: Limonene capsules(Placebo)
Study: NCT05897671

Intervention type: OTHER
Intervention: retrospective data analysis
Description: Macular hole closure rate, visual acuity and OCT
Study: NCT05003544

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group A
Description: PENG BLOCK

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group B
Description: Intra-articular

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group C
Description: Quadratus lumborum block
Study: NCT03905083

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Rehab
Description: Participants who do the Exercise Rehab will engage in up to four center-based exercise rehab sessions each week for approximately 12 weeks; each session lasting roughly 1-hour with a stimulus (exercise) phase and a mix of warm up and cool down. Cycle ergometer and treadmill exercise may be used.
Study: NCT05781672

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: cardiac ultrasound with speckle tracking analysis
Description: Experimental group: cardiac ultrasound with speckle tracking analysis done during a regular cardiac visit planned after receiving cardiotoxic chemotherapy in childhood.~Control group: cardiac ultrasound with speckle tracking analysis done during a cardiac visit for minor symptoms (murmur, physical aptitude).~Advocated Tomtec software will be used to make post-processing speckle tracking analysis based on 2D ultrasound cineloop acquired during a standard echocardiography.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: cardiac ultrasound with speckle tracking analysis
Description: Experimental group: cardiac ultrasound with speckle tracking analysis done during a regular cardiac visit planned after receiving cardiotoxic chemotherapy in childhood.~Control group: cardiac ultrasound with speckle tracking analysis done during a cardiac visit for minor symptoms (murmur, physical aptitude).~Advocated Tomtec software will be used to make post-processing speckle tracking analysis based on 2D ultrasound cineloop acquired during a standard echocardiography.
Study: NCT04879017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FHD-286
Description: FHD-286 as a single agent
Study: NCT04489134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selection visit:
Description: During this visit, it will be asked to sign the following consent and it will be carried out:~* a clinical examination (questioning and physical examination with measurement of height and weight);~* a blood test (18 mL);~* a blood pregnancy test if you are a woman;~* a cardiac assessment (electrocardiogram).~These results should be normal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selection visit:
Description: During this visit, it will be asked to sign the following consent and it will be carried out:~* a clinical examination (questioning and physical examination with measurement of height and weight);~* a blood test (18 mL);~* a blood pregnancy test if you are a woman;~* a cardiac assessment (electrocardiogram).~These results should be normal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selection visit:
Description: During this visit, it will be asked to sign the following consent and it will be carried out:~* a clinical examination (questioning and physical examination with measurement of height and weight);~* a blood test (18 mL);~* a blood pregnancy test if you are a woman;~* a cardiac assessment (electrocardiogram).~These results should be normal.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selection visit:
Description: During this visit, it will be asked to sign the following consent and it will be carried out:~* a clinical examination (questioning and physical examination with measurement of height and weight);~* a blood test (18 mL);~* a blood pregnancy test if you are a woman;~* a cardiac assessment (electrocardiogram).~These results should be normal.